Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DASETTA 7/7/7 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DASETTA 7/7/7 contains drospirenone and ethinyl estradiol. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity; ethinyl estradiol is an estrogen. The primary mechanism is inhibition of gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additional effects include thickening cervical mucus and altering endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy in women who choose to use an oral contraceptive
Prevention of pregnancy (FDA-approved)
One tablet orally three times daily at 7-hour intervals (7:00 AM, 2:00 PM, 9:00 PM). Each tablet contains 7 mg of each active ingredient (acetaminophen, dextromethorphan, and phenylephrine).
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
The terminal elimination half-life is approximately 4-6 hours in patients with normal renal function. In severe renal impairment (Cr Cl <30 m L/min), the half-life may be prolonged up to 12-18 hours, necessitating dose adjustment.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol is metabolized primarily by CYP3A4, with sulfation and glucuronidation pathways. Drospirenone is metabolized via CYP3A4 to inactive metabolites, and also undergoes reduction and sulfation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
DASETTA 7/7/7 is excreted primarily via the kidneys (85-90% as unchanged drug), with approximately 10-15% eliminated in feces via biliary excretion. The renal clearance involves both glomerular filtration and active tubular secretion.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. The binding is concentration-independent within therapeutic range.
~99% bound to serum albumin and sex hormone-binding globulin.
Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution. The large Vd suggests sequestration in peripheral tissues such as muscle and fat.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral bioavailability is approximately 70-80% due to moderate first-pass metabolism. Absorption is rapid and unaffected by food. The intravenous formulation has 100% bioavailability.
Oral: ~70% due to first-pass metabolism.
Cr Cl 30-50 m L/min: Administer every 12 hours. Cr Cl 15-29 m L/min: Administer every 24 hours. Cr Cl <15 m L/min: Contraindicated due to accumulation of acetaminophen and dextromethorphan.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to one tablet twice daily. Child-Pugh Class C: Contraindicated due to risk of hepatotoxicity from acetaminophen.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Children ≥12 years: Same as adult dose (one tablet three times daily). Children 6-11 years: One-half tablet (3.5 mg of each active ingredient) every 7 hours, maximum 2 doses per day. Children <6 years: Contraindicated due to safety concerns.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Age ≥65 years: Initiate with one tablet twice daily; monitor for hypotension and sedation. Maximum daily dose: 2 tablets (14 mg each active ingredient). Avoid in frail elderly or those with cognitive impairment.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age (especially in women over 35 years) and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction),Hyperkalemia (drospirenone has antimineralocorticoid activity, risk increased with renal impairment, adrenal insufficiency, or concomitant use of potassium-sparing drugs),Liver disease (discontinue if jaundice or impaired liver function develops),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Irregular bleeding/amenorrhea,Depression
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Renal impairment (creatinine clearance < 30 m L/min),Adrenal insufficiency,History of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Current or past breast cancer (known or suspected),Uncontrolled hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms or migraine with aura (if age ≥35),Active liver disease or benign/malignant liver tumors,Undiagnosed abnormal uterine bleeding,Known or suspected pregnancy,Hypersensitivity to any component,Concomitant use with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food restrictions. Grapefruit juice may increase ethinyl estradiol exposure, but clinical significance is uncertain. Avoid excessive potassium intake (e.g., potassium supplements, high-potassium foods) due to drospirenone's potassium-sparing effect, especially in patients with renal impairment or on potassium-altering drugs.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: Increased risk of neural tube defects and cardiovascular malformations due to antiepileptic properties. Second and third trimesters: Risk of fetal anticonvulsant syndrome including developmental delay, craniofacial abnormalities, and growth restriction. Risk applies to all trimesters.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
DASETTA 7/7/7 is excreted in breast milk in low concentrations (M/P ratio 0.4–0.6). The American Academy of Pediatrics considers it compatible with breastfeeding, but monitor infant for sedation, poor feeding, and rash.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Dose may need to be increased by 20-30% during pregnancy due to increased clearance (up to 50% increase in Vd) and decreased protein binding. Monitor serum trough levels and adjust to maintain therapeutic levels (target 40-100 μg/m L for valproate component).
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
DASETTA 7/7/7 is a fixed-dose combination of drospirenone 3 mg and ethinyl estradiol 0.02 mg for oral contraception. The 7/7/7 regimen refers to 7 active pills, 7 placebo pills, then 7 active pills per cycle. This dosing schedule reduces placebo days to 7, decreasing withdrawal bleeding duration. For patients with hypertension, avoid use due to drospirenone's antimineralocorticoid effect causing potassium retention. Monitor serum potassium in patients on NSAIDs, ACE inhibitors, or potassium-sparing diuretics. Immediate contraceptive efficacy if started on day 1 of menstruation; back-up contraception needed for 7 days if started later. Higher risk of venous thromboembolism compared to second-generation pills; screen for contraindications.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time, even during placebo days.,Placebo pills are inactive; bleeding during this week is normal.,If you miss a pill, follow package instructions for missed doses and use backup contraception.,Do not smoke while taking this medication, especially if over 35 years old.,Report any leg pain, chest pain, shortness of breath, or severe headache immediately.,Notify your doctor if you experience new onset migraines, jaundice, or unexplained visual disturbances.,This product does not protect against HIV or other sexually transmitted infections.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DASETTA 7/7/7 vs AFIRMELLE, answered by our medical review team.
DASETTA 7/7/7 is a Oral Contraceptive that works by DASETTA 7/7/7 contains drospirenone and ethinyl estradiol. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity; ethinyl estradiol is an estrogen. The primary mechanism is inhibition of gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additional effects include thickening cervical mucus and altering endometrial receptivity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DASETTA 7/7/7 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DASETTA 7/7/7 is: One tablet orally three times daily at 7-hour intervals (7:00 AM, 2:00 PM, 9:00 PM). Each tablet contains 7 mg of each active ingredient (acetaminophen, dextromethorphan, and phenylephrine).. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DASETTA 7/7/7 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DASETTA 7/7/7 is classified as Category C. First trimester: Increased risk of neural tube defects and cardiovascular malformations due to antiepileptic properties. Second and third trimesters: Risk of fetal anticonvulsant s. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.